Immunocore Holdings plc (NASDAQ:IMCR) Stock Position Raised by GAMMA Investing LLC

GAMMA Investing LLC grew its stake in Immunocore Holdings plc (NASDAQ:IMCR - Free Report) by 3,318.1% during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 19,107 shares of the company's stock after purchasing an additional 18,548 shares during the quarter. GAMMA Investing LLC's holdings in Immunocore were worth $5,670,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently bought and sold shares of IMCR. Assetmark Inc. raised its stake in Immunocore by 5.3% during the fourth quarter. Assetmark Inc. now owns 32,171 shares of the company's stock worth $949,000 after acquiring an additional 1,616 shares during the period. Primecap Management Co. CA raised its stake in Immunocore by 8.0% during the fourth quarter. Primecap Management Co. CA now owns 2,668,550 shares of the company's stock worth $78,722,000 after acquiring an additional 196,530 shares during the period. BIT Capital GmbH raised its stake in Immunocore by 182.7% during the fourth quarter. BIT Capital GmbH now owns 67,840 shares of the company's stock worth $2,001,000 after acquiring an additional 43,840 shares during the period. NEOS Investment Management LLC raised its stake in Immunocore by 10.9% during the fourth quarter. NEOS Investment Management LLC now owns 11,194 shares of the company's stock worth $330,000 after acquiring an additional 1,102 shares during the period. Finally, Geode Capital Management LLC raised its stake in Immunocore by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 35,492 shares of the company's stock worth $1,047,000 after acquiring an additional 420 shares during the period. Institutional investors and hedge funds own 84.50% of the company's stock.

Insider Activity at Immunocore

In other Immunocore news, Director Bros. Advisors Lp Baker bought 807,338 shares of the business's stock in a transaction that occurred on Monday, March 17th. The stock was acquired at an average cost of $29.72 per share, with a total value of $23,994,085.36. Following the completion of the purchase, the director now directly owns 2,144,060 shares in the company, valued at approximately $63,721,463.20. This trade represents a 60.40% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. Company insiders own 10.40% of the company's stock.

Analyst Upgrades and Downgrades

IMCR has been the topic of several research reports. Mizuho dropped their price objective on shares of Immunocore from $38.00 to $33.00 and set a "neutral" rating on the stock in a research note on Monday, April 7th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Immunocore in a research report on Tuesday, May 27th. They issued a "buy" rating and a $65.00 target price for the company. Wall Street Zen cut shares of Immunocore from a "buy" rating to a "hold" rating in a research report on Friday, June 6th. HC Wainwright restated a "buy" rating and issued a $100.00 target price on shares of Immunocore in a research report on Monday, June 2nd. Finally, Oppenheimer upped their target price on shares of Immunocore from $85.00 to $86.00 and gave the stock an "outperform" rating in a research report on Thursday, May 8th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and seven have given a buy rating to the company. According to MarketBeat, Immunocore presently has a consensus rating of "Moderate Buy" and a consensus price target of $58.89.

Immunocore Price Performance

Shares of Immunocore stock traded down $0.95 on Friday, hitting $34.68. The company had a trading volume of 435,478 shares, compared to its average volume of 363,326. The business has a 50-day simple moving average of $30.85 and a 200-day simple moving average of $30.29. The company has a debt-to-equity ratio of 1.03, a current ratio of 3.78 and a quick ratio of 3.76. The company has a market cap of $1.74 billion, a PE ratio of -36.50 and a beta of 0.83. Immunocore Holdings plc has a 52 week low of $23.15 and a 52 week high of $41.54.

Immunocore (NASDAQ:IMCR - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.45. The business had revenue of $125.13 million during the quarter, compared to analysts' expectations of $108.82 million. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%. The business's revenue was up 33.6% on a year-over-year basis. During the same period last year, the firm posted ($0.49) earnings per share. Research analysts expect that Immunocore Holdings plc will post -0.94 EPS for the current fiscal year.

Immunocore Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.